Bayer Xarelto reduced the risk of heart failure compared to vitamin K antagonists (VKA) in patients with nonvalvular atrial fibrillation (NVAF) with chronic kidney disease (CKD). Bayer Korea shared the presentation of the XARENO study, a prospective observational study on nonvalvular atrial fibrillation patients with chronic kidney disease, at the 71st annual meeting of the American Heart Association (ACC 2022) on the 5th.
XARENO conducted the first prospective observational study, XARENO, of patients with NVAF with advanced chronic kidney disease, comparing patients with VKA or patients not taking oral anticoagulants (at the discretion of the attending physician) with patients with NVAF. .
After one year of follow-up in the XARENO study, Xarelto showed a greater total clinical benefit and a lower risk of renal failure compared to VKA in NVAF patients with advanced chronic kidney disease.
Professor Reinhold Kreutz, Department of Clinical Pharmacy, Charité Medical University, Berlin, said: “Chronic kidney disease is a common condition, but it tends to be underestimated despite its serious impact on the patient’s quality of life, including death depending on the stage.” “The XARENO study will provide important evidence for medical staff treating patients with atrial fibrillation with chronic kidney disease, and will help reduce the patient’s risk of progression to renal failure.”
Chronic kidney disease is an independent risk factor for cardiovascular disease, and it is estimated that 15-20% of patients with atrial fibrillation also have chronic kidney disease. Because patients with atrial fibrillation with impaired renal function have a higher risk of stroke and bleeding, preventing renal function decline in the selection of oral anticoagulants for patients with atrial fibrillation is an important treatment goal that should be considered in addition to stroke prevention.
Following ROCKET-AF, which is a randomized controlled trial (RCT) study, Xarelto added evidence of prescription in patients with renal impairment, including stage 4 patients with chronic kidney disease. Through the XARENO study, Xarelto has prepared a wider clinical basis compared to other NOACs (New Oral Anticoagulants) in the preservation of renal function.
The 2019 American Heart Association, Heart Association, and Arrhythmia Society (AHA, ACC, HRS) guidelines are different from other NOACs with a trough of the therapeutic range in patients with atrial fibrillation with renal impairment. It is recommended for use in patients with less than
“Previous studies evaluating stroke prevention in patients with atrial fibrillation excluded patients with advanced chronic kidney disease,” said Michael Devoy, Head of Medicine, Bayer. “The XARENO study provided important clues to prevent disease progression and improve clinical prognosis in patients with atrial fibrillation with chronic kidney disease.”
